Protalix BioTherapeutics, Inc. (PLX)

Healthcare · Biological Products, (No Diagnostic Substances) · Price $2.40
Updated: Aug 21, 2026
Net Income (TTM)
$18.9M
Trailing 12 Months
Growth Rate
-36.41%
Log-Linear Regression (16Q)
Price/Earnings
10.0x
Valuation Multiple
EPS (Diluted)
$0.24
Net Income / Shares
Net Margin
23.50%
Profitability

📈 Net Income History (16 Quarters)

🧮 PLX Net Income Breakdown

Net Income = Revenue - All Expenses - Taxes - Interest
Revenue (Top Line) $80.6M
Less: Cost of Revenue → Gross Profit $55.8M
Less: Operating Expenses → Operating Income $23.3M
Less: Interest Expense N/A
Less: Income Tax Expense $4.5M
Equals: Net Income (Bottom Line) $18.9M

Understanding Net Income

Net income, also called the "bottom line" or net profit, is the money a company keeps after paying all expenses including cost of goods, operating costs, interest, and taxes. For PLX, the trailing twelve month net income is $18.9M.

Why Net Income Matters

Net income is the ultimate measure of accounting profitability. It determines earnings per share (EPS), affects stock valuations through the P/E ratio, and represents the theoretical amount available to shareholders. However, net income can be influenced by accounting choices, which is why value investors often look at cash flow metrics alongside it.

PLX's net income growth rate of -36.41% (based on log-linear regression of 16 quarters) indicates significant profit decline, requiring investigation into causes.

Net Income vs Cash Flow Metrics

Free Cash Flow: $13.0M →

Actual cash generated after capital expenditures. FCF often differs from net income due to depreciation, working capital changes, and capex timing.

Owner Earnings: $13.6M →

Buffett's preferred metric that adds back depreciation but subtracts maintenance capex. Often considered more accurate than net income.

EPS (Diluted): $0.24 →

Net income divided by diluted shares outstanding. The primary driver of the P/E ratio used in valuations.

Revenue: $80.6M →

The top line that net income is derived from. Net margin shows what percentage of revenue becomes profit.

P/E Ratio Analysis

PLX's P/E ratio of 10.0x means investors pay $10.00 for every $1 of annual earnings. A P/E between 10-15 is typical for mature, slow-growth companies with stable earnings.

Net Margin: Profitability Efficiency

Net margin of 23.50% shows what percentage of PLX's revenue converts to profit after all costs. Net margins above 20% are excellent and indicate strong pricing power or asset-light business models.

Summary: PLX Net Income Trend

Protalix BioTherapeutics, Inc. (PLX) has a net margin of 23.50%, which Zyberno classifies as excellent for a Healthcare company — above the 18% threshold Zyberno applies to healthcare businesses where R&D amortization, legal costs, and tax structures shape net margins. Net income grew at -36.41% annually — a material decline Zyberno treats as a concern requiring investigation. For complete financial analysis, view the full PLX stock report on Zyberno.

Frequently Asked Questions

What is PLX's current net income?

Protalix BioTherapeutics, Inc.'s TTM net income is $18.9M, growing at -36.41% annually — a material decline Zyberno treats as a concern requiring investigation.

Is PLX's net income growing?

Protalix BioTherapeutics, Inc. (PLX) has a net margin of 23.50%, which Zyberno classifies as excellent for a Healthcare company — above the 18% threshold Zyberno applies to healthcare businesses where R&D amortization, legal costs, and tax structures shape net margins. Net income grew at -36.41% annually — a material decline Zyberno treats as a concern requiring investigation.

What is PLX's net profit margin?

Protalix BioTherapeutics, Inc. (PLX) has a net margin of 23.50%, which Zyberno classifies as excellent for a Healthcare company — above the 18% threshold Zyberno applies to healthcare businesses where R&D amortization, legal costs, and tax structures shape net margins. Net income grew at -36.41% annually — a material decline Zyberno treats as a concern requiring investigation.

What is PLX's P/E ratio?

PLX's P/E ratio is 10.0x, meaning the market values the company at 10.0 times its annual earnings.

How does net income differ from free cash flow?

Net income is an accounting measure that includes non-cash items like depreciation, while free cash flow shows actual cash generated. PLX's net income is $18.9M versus free cash flow of $13.0M. Large differences often indicate significant capital expenditures or working capital changes.

📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
$5.28
🛡️
Margin of Safety
Valuation Gap
54.5%
🎯
Expected Return
Projected Annual
41.0%
Click any metric for full methodology and detailed analysis

📊 Full PLX Stock Report

See PLX's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

💵 PLX Free Cash Flow

Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.

💰 PLX Owner Earnings

Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.

📈 PLX Earnings Per Share

Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.

🎯 PLX Earnings Surprise (SUE)

See whether PLX is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

📊 PLX Revenue

Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.

💰 PLX Net Income

Analyze the bottom-line profit, P/E ratio, and net profit margin trends.

🔶 PLX Operating Income

Analyze EBIT, operating margin, and core business profitability before interest and taxes.

💜 PLX Gross Profit

Analyze gross margin, pricing power, and profitability before operating expenses.

View Full PLX Report Find More Quality Stocks
Scroll to Top